Perelman School of Medicine at the University of Pennsylvania

Drapkin Lab

Header Image

Publications

Representative Publications

pubmed logo

       Click here for a complete listing on PubMed.        Click here for the Research Gate page.

 

2017

  High grade serous ovarian carcinomas originate in the fallopian tube.
Labidi-Galy SI*, Papp E*, Hallberg D, Niknafs N, Adleff V, Noe M, Bhattacharya R, Novak M, Jones S, Phallen J, Hruban CA, Hirsch MS, Lin DI, Schwartz L, Maire CL, Tille JC, Bowden M, Ayhan A, Wood LD, Scharpf RB, Kurman R, Wang TL, Shih IM, Karchin R, Drapkin R#, Velculescu VE#.
* Denotes equal contribution. # Denotes co-senior/co-corresponding authors.
Nature Communications (2017); 8(1): 1093.

Article Coverage and Highlights

 

  Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response.
Zervantonakis IK, Iavarone C, Chen HY, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis U, Leverson JD, Sampath D, Mills GB, Brugge JS.
Nature Communications (2017); 8(1): 365.

  Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.
Samimi G, Bernardini MQ, Brody LC, Caga-Anan CF, Campbell IG, Chenevix-Trench G, Couch FJ, Dean M, de Hullu JA, Domchek SM, Drapkin R, Spencer Feigelson H, Friedlander M, Gaudet MM, Harmsen MG, Hurley K, James PA, Kwon JS, Lacbawan F, Lheureux S, Mai PL, Mechanic LE, Minasian LM, Myers ER, Robson ME, Ramus SJ, Rezende LF, Shaw PA, Slavin TP, Swisher EM, Takenaka M, Bowtell DD, Sherman ME.
J Clin Oncol (2017); 35: 2329-2337.

  PRKCI promotes immune suppression in ovarian cancer.
Sarkar S, Bristow CA, Dey P, Rai K, Perets R, Ramirez-Cardenas A, Malasi S, Huang-Hobbs E, Haemmerle M, Wu SY, McGuire M, Protopopov A, Jiang S, Liu JF, Hirsch MS, Chang Q, Lazar AJ, Sood AK, Drapkin R, DePinho R, Draetta G, Chin L.
Genes Dev (2017); 31: 1109-1121.

  Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer.
Medrano M, Communal L, Brown KR, Iwanicki M, Normand J, Paterson J, Sircoulomb F, Krzyzanowski P, Novak M, Doodnauth SA, Saiz FS, Cullis J, Al-Awar R, Neel BG, McPherson J, Drapkin R, Ailles L, Mes-Massons AM, Rottapel R.
Cell Reports (2017); 18:2343-2358.

  Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
Au-Yeung G, Lang F, Azar WJ, Mitchell C, Jarman KE, Lackovic K, Aziz D, Cullinane C, Pearson RB, Mileshkin L, Rischin D, Karst AM, Drapkin R, Etemadmoghadam D, Bowtell DD.
Clin Cancer Res. (2017); 23(7): 1862-74.

  Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for pre-clinical evaluation of novel therapeutics.
Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, Zheng M, Adleff V, Papp E, Piao H, Novak M, Fotheringham S, Wulf G, English J, Kirschmeier PT, Velculescu VE, Paweletz CP, Mills GB, Livingston DM, Brugge JS, Matulonis UA, Drapkin R.
Clin Cancer Res. (2017); 23:1263-1273.

  Pathogenesis and heterogeneity of ovarian cancer.
Kroeger PT Jr, Drapkin R.
Curr Opin Obstet Gynecol (2017); 29(1):26-34.

  A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.
George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R., Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F.
JCI Insight (2017); 2(1):e89760.

Close


2016

  Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors.
Elias KM, Emori MM, Westerling T, Long H, Budina-Kolomets A, Li F, MacDuffie E, Davis MR, Holman A, Lawney B, Freedman ML, Quackenbush J, Brown M, Drapkin R.
JCI Insight (2016); 1(13): e87988.

Article Coverage and Highlights


 
  Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.
Sherman ME, Drapkin RI, Horowitz NS, Crum CP, Friedman S, Kwon JS, Levine DA, Shih IeM, Shoupe D, Swisher EM, Walker J, Trabert B, Greene MH, Samimi G, Temkin SM, Minasian LM.
Cancer Prev Res (2016); 9 (9): 713-20.
 
  CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma.
Kuhn E, Wang TL, Doberstein K, Bahadirli-Talbott A, Ayhan A, Sehdev AS, Drapkin R, Kurman RJ, Shih IM.
Mod Pathol (2016), [Epub ahead of print].

  Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.
Iwanicki MP, Chen H-Y, Iavarone C, Zervantonakis IK, Muranen T, Novak M, Ince TA, Drapkin R*, Brugge JS*.
JCI Insight 2016; 1 (10): e86829. *co-corresponding authors

  Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model.
Chang D-K, Peterson E, Sun J, Goudie C, Drapkin RI, Liu JF, Matulonis U, Zhu Q, Marasco WA.
OncoImmunology (2016); 5: e1090075.

  Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment.
Wang S, Blois A, El Rayes T, Liu JF, Hirsch MS, Gravdal K, Palakurthi S, Bielenberg DR, Akslen LA, Drapkin R, Mittal V, Watnick RS.
Sci Transl Med. (2016); 8(329):329ra34.

  Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.
Choi YE, Meghani K, Brault ME, Leclerc L, He YJ, Day TA, Elias KM, Drapkin R, Weinstock DM, Dao F, Shih KK, Matulonis U, Levine DA, Konstantinopoulos PA, Chowdhury D.
Cell Rep.(2016); 14:429-39.

  It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research.
Perets R, Drapkin R.
Cancer Res. (2016);  76:10-7.

Close


2015

  Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis.
Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NM, Nagaraja AS, Gharpure KM, McGuire M, Sam N, Armaiz-Pena GN, Sadaoui NC, Rodriguez-Aguayo C, Calin GA, Drapkin RI, Kovacs J, Mills GB, Zhang W, Lopez-Berestein G, Bhattacharya PK, Sood AK.
Cell Reports (2015); 13: 2395-402.
 
  Elafin: a double agent in breast and ovarian cancer.
Feng Y, Doberstein K, Drapkin R.
Oncoscience (2015); 2: 793-4.
 
  Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR.
Nature Rev Cancer (2015);15: 668-79.
 
  PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth.
Montal ED, Dewi R, Bhalla K, Ou L, Hwang BJ, Ropell AE, Gordon C, Liu WJ, DeBerardinis RJ, Sudderth J, Twaddel W, Boros LG, Shroyer KR, Duraisamy S, Drapkin R, Powers RS, Rohde JM, Boxer MB, Wong KK, Girnun GD.
Mol Cell (2015); 60:571-83.
 
  Role of miR-182 in response to oxidative stress in the cell fate of human fallopian tube epithelial cells.
Liu Y, Qiang W, Xu X, Dong R, Karst AM, Liu Z, Kong B, Drapkin RI, Wei JJ.
Oncotarget (2015); 6: 38983-98.
 
  YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells.
Hua G, Lv X, He C, Remmenga SW, Rodabough KJ, Dong J, Yang L, Lele SM, Yang P, Zhou J, Karst A, Drapkin RI, Davis JS, Wang C. Oncogene (2015) [Epub ahead of print].
 
  Beyond genomics: critical evaluation of cell line utility for ovarian cancer research.
Elias KM, Emori MM, Papp E, MacDuffie E, Konecny GE, Velculescu VE, Drapkin R.
Gynecol Oncol (2015); 139: 97-103.
 
  Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma.
Novak M, Lester J, Karst AM, Parkash V, Hirsch MS, Crum CP, Karlan BY, Drapkin R.
Gynecol Oncol (2015); 139: 104-11.
 
  GATA3 is a Sensitive and Specific Marker of Benign and Malignant Mesonephric Lesions in the Lower Female Genital Tract.
Howitt BE, Emori MM, Drapkin R, Gaspar C, Barletta JA, Nucci MR, McCluggage WG, Oliva E, Hirsch MS.
Am J Surg Pathol (2015); 39: 1411-9.
 
  Tumor-Targeting Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle.
Dreaden EC, Kong YW, Morton SW, Correa S, Choi KY, Shopsowitz KE, Renggli K, Drapkin R, Yaffe MB, Hammond PT.
Clin Cancer Res (2015); 21: 4410-9.
 
  Whole-genome characterization of chemoresistant ovarian cancer.
Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD.
Nature (2015); 521:489-94.
 
  Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array.
Vathipadiekal V, Wang V, Wei W, Waldron L, Drapkin R, Gillette M, Skates S, Birrer M.
Clin Cancer Res (2015); 21: 4960-9.
 
  Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci.
Coetzee SG, Shen HC, Hazelett DJ, Lawrenson K, Kuchenbaecker K, Tyrer J, Rhie SK, Levanon K, Karst A, Drapkin R, Ramus SJ; Ovarian Cancer Association Consortium, The Consortium of Investigators of Modifiers of BRCA1/2, Couch FJ, Offit K, Chenevix-Trench G, Monteiro AN, Antoniou A, Freedman M, Coetzee GA, Pharoah PD, Noushmehr H, Gayther SA; Ovarian Cancer Association Consortium The Consortium of Investigators of Modifiers of BRCA1/2.
Human Mol Genet (2015); 24: 3595-607.
 
  GATA3 expression in gestational trophoblastic tissues and tumours.
Mirkovic J, Elias K, Drapkin R, Barletta JA, Quade B, Hirsch MS.
Histopathology (2015); 67: 636-44.
 
  Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.
Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Janne PA, Armein PC, Cichowski K, Drapkin R, Letai A.
Cell (2015); 160: 977-89.
 
  An in-tumor genetic screens reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma.
Baratta MG, Schinzel AC, Zwang Y, Bandopadhayay P, Bowman-Colin C, Kutt J, Curtis J, Piao H, Wong LC, Kung AL, Beroukhim R, Bradner JE, Drapkin R, Hahn WC, Liu JF, Livingston DM.
Proc Natl Acad Sci USA (2015); 112: 232-7.
 
  Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer.
Russell S, Duquette M, Liu J, Drapkin R, Lawler J, Petrik J.
FASEB J. (2015); 29: 576-88.
 
  Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors.
Labidi-Galy SI, Clauss A, Ng V, Duraisamy S, Elias KM, Piao HY, Bilal E, Davidowitz RA, Lu Y, Badalian-Very G, Györffy B, Kang UB, Ficarro S, Ganesan S, Mills GB, Marto JA, Drapkin R.
Oncogene (2015); 34: 373-83.

Close


2014

  Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance.
Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R.*, Brugge JS*. * co-corresponding.
J Clin Invest (2014); 124: 2611-25.

Article Coverage and Highlights

  Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women.
Karlan BY, Thorpe J, Watabayashi K, Drescher CW, Palomares M, Daly MB, Paley P, Hillard P, Andersen MR, Anderson G, Drapkin R., Urban N.
Cancer Epidemiol Biomarkers Prev (2014); 23: 1383-93.

  The hormonal composition of follicular fluid and its implications for ovarian cancer pathogenesis.
Emori MM, Drapkin R.
Reprod Biol Endocrinol (2014); 12: 6

  Highlights from the 2014 American Association for Cancer Research Annual Meeting.
Bowtell DD, Drapkin R.
Gyn Oncol (2014); 134: 3-5.

  In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene.
Dunn GP, Cheung HW, Agarwalla PK, Zektser Y, Karst AM, Boehm JS, Weir BA, Berlin AM, Zou L, Getz G, Liu JF, Hirsch MS, Vazquez F, Root DE, Beroukhim R, Drapkin R., Hahn WC.
PNAS (2014); 111: 1102-7.

  Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.
Karst AM, Jones PM, Vena N, Ligon AH, Liu JF, Hirsch MS, Etemadmoghadam D, Bowtell DD, Drapkin R.
Cancer Res (2014); 74: 1141-52.

  Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms.
Elias KM, Labidi-Galy SI, Vitonis AF, Hornick JL, Doyle LA, Hirsch MS, Cramer DW, Drapkin R.
Gynecol Oncol (2014); 132: 328-33.

  FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis.
Levanon K, Sapoznik S, Bahar-Shany K, Brand H, Shapira-Frommer R, Korach J, Hirsch MS, Roh MH, Miron A, Liu JF, Vena N, Ligon AH, Fotheringham S, Bailey D, Flavin RJ, Birrer MJ, Drapkin R.
Oncogene (2014) [Epub ahead of print].

Close


2013

  Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca; Tp53; Pten models.
Perets R, Wyant GA, Muto, Bijron JG, Poole BB, Chin KT, Chen JYH, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, Setlur SR, Crum CP, Dinulescu DM, Drapkin R.
Cancer Cell (2013); 24: 751-765.

Article Coverage and Highlights

  Coming into focus: the nonovarian origins of ovarian cancer.
Dubeau L and Drapkin R.
Annals of Oncology (2013); 24 (Suppl 8): viii28-viii35.

  Modeling high-grade serous carcinoma: how converging insights into pathogenesis and genetics are driving better experimental platforms.
Jones PM, Drapkin R,
Front. Oncol. (2013); 3:217. doi: 10.3389/fonc.2013.00217

  HE4 (WFDC2) promotes tumor growth in endometrial cancer cell lines.
Li J, Chen H, Mariani A, Chen D, Klatt E, Podratz K, Drapkin R, Broaddus R, Dowdy S, Jiang S-W.
Int J Mol Sci 2013; 14: 6026-6043.

  Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas.
O’Neal RL, Nam KT, LaFleur BJ, Barlow B, Nozaki K, Lee H-J, Kim WH, Yang H-K, Shi C, Maitra A, Montgomery E, Washington MK, El Rifai W, Drapkin RI, Goldenring JR.
Human Pathol 2013; 44: 734-742.

  Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers.
Sung CK, Li D, Andrews E, Drapkin R, Benjamin T.
Mol Oncol (2013); 7: 419-427.

  Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.
Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, Levanon K, Sougnez C, Tsherniak A, Gomez S, Onofrio R, Gabriel S, Chin L, Zhang N, Spellman PT, Zhang Y, Akbani R, Hoadley KA, Kahn A, Kobel M, Huntsman D, Soslow RA, Defazio A, Birrer MJ, Gray JW, Weinstein JN, Bowtell DD, Drapkin R, Mesirov JP, Getz G, Levin DA, Meyerson M.
J Clin Invest (2013); 123: 517-25.

  Stathmin-1 expression as a complement to p16 helps identify high-grade cervical intraepithelial neoplasia with increased specificity.
Howitt BE, Nucci MR, Drapkin R, Crum CP, Hirsch MS.
Am J Surg Pathol (2013); 37: 89-97.

Close


2012

  The Polyoma Virus Large T Binding Protein p150 Is a Transcriptional Repressor of c-MYC.
Sung CK, Yim H, Gu H, Li D, Andrews E, Duraisamy S, Li C, Drapkin R, Benjamin T.
PLoS One (2012); 7(9): e46486.

  Primary culture and immortalization of human fallopian tube secretory epithelial cells.
Karst AM, Drapkin R.
Nature Protocols (2012); 7: 1755-1764.

  Targeted Tumor-Penetrating siRNA Nanocomplexes for Credentialing the Ovarian Cancer Oncogene ID4.
Ren Y, Cheung HW, von Maltzhan G, Agrawal A, Cowley GS, Weir BA, Boehm JS, Tamayo P, Karst AM, Liu JF, Hirsch MS, Mesirov JP, Drapkin R, Root DE, Lo J, Fogal V, Ruoslahti E, Hahn WC, Bhatia SN.
Science Transl. Med. (2012); 4: 147ra112.

  Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.
Wang ZC, Birkbak NJ, Culhane A, Drapkin RI, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, Defazio A, Quackenbush J, Berkowitz RS, Iglehart JD, Bowtell DD, Matulonis UA.
Clin Cancer Res (2012); 18: 5806-5815

  Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian Cancer.
Bentink S, Haibe-Kains B, Risch T, Fan JB, Hirsch MS, Holton K, Rubio R, April C, Chen J, Wickham-Garcia E, Liu J, Culhane A, Drapkin R, Quackenbush J, Matulonis UA.
PLoS One. (2012); 7(2): e30269.

  Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.
Engler DA, Gupta S, Growdon WB, Drapkin RI, Nitta M, Sergent PA, Allred SF, Gross J, Deavers MT, Kuo WL, Karlan BY, Rueda BR, Orsulic S, Gershenson DM, Birrer MJ, Gray JW, Mohapatra G.
PLoS One. (2012); 7(2): e30996.

  The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer.
Manchanda R, Drapkin R, Jacobs I, Menon U.
Gynecol Oncol (2012) 124:185-91.

  ErbB2, EphrinB1, Src Kinase and PTPN13 Signaling Complex Regulates MAP Kinase Signaling in Human Cancers.
Vermeer PD, Bell M, Lee K, Vermeer DW, Wieking BG, Bilal E, Bhanot G, Drapkin RI, Ganesan S, Klingelhutz AJ, Hendriks WJ, Lee JH.
PLoS One. (2012); 7(1):e30447.

Close


2011

  The new face of ovarian cancer modeling: better prospects for detection and treatment.
Karst AM, Drapkin R.
Faculty 1000 Med Rep (2011) 3:22.

  Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.
Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, Deangelo DJ, McConkey DJ, Sallan SE, Silverman L, Hirsch MS, Carrasco DR, Letai A.
Science (2011) 334:1129-33.

  Rethinking ovarian cancer: recommendations for improving outcomes.
Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR.
Nature Reviews Cancer (2011) 11: 719-725.

  Aberrant Expression of the Dendritic Cell Marker TNFAIP2 by the Malignant Cells of Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma Distinguishes These Tumor Types From Morphologically and Phenotypically Similar Lymphomas.
Kondratiev S, Duraisamy S, Unitt CL, Green MR, Pinkus GS, Shipp MA, Kutok JL, Drapkin R, Rodig SJ.
Am J Surg Pathol (2011) 35: 1531-9.

  High Throughput Interrogation of Somatic Mutations in High Grade Serous Cancer of the Ovary.
Matulonis UA, Hirsch M, Palescandolo E, Kim E, Liu J, van Hummelen P, MacConaill L, Drapkin R, Hahn WC.
PLoS ONE (2011) 6(9): e24433.
    
  Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas.
Karst AM, Levanon K, Duraisamy S, Liu JF, Hirsch MS, Hecht JL, Drapkin R.
Gynecol Oncol (2011) 123: 5-12.

Article Coverage and Highlights     

  Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer.
Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA, East A, Ali LD, Lizotte PH, Wong TC, Jiang G, Hsiao J, Mermel CH, Getz G, Barretina J, Gopal S, Tamayo P, Gould J, Tsherniak A, Stransky N, Luo B, Ren Y, Drapkin R., Bhatia SN, Mesirov JP, Garraway LA, Meyerson M, Lander ES, Root DE, Hahn WC.
PNAS (2011) 108:12372-7.
    
  Modeling high-grade serous ovarian carcinogenesis from the fallopian tube.
Karst AM, Levanon K, Drapkin R.
PNAS (2011) 108: 7547-7552.

Article Coverage and Highlights     Inside The Institute | Nature Cancer Review | JNCI

  Ex vivo culture of primary human fallopian tube epithelial cells.
Fotheringham S, Levanon K, Drapkin R.
J Vis Exp (2011) 51: http://www.jove.com/details.stp?id=2728 doi: 10.3791/2728.

  A comprehensive analysis of Pax8 expression in human epithelial tumors.
Laury A, Perets R, Piao H, Krane JF, Barletta JA, French C, Chirieac LR, Lis R, Loda M, Hornick JL, Drapkin R, Hirsch MS.
Am J Surg Pathol (2011) 35: 816-826.

Close


2010

  53BP1 Loss Rescues BRCA1 Deficiency and is Associated with Triple-Negative and BRCA-Mutated Breast Cancers.
Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, Haffty BG, Tommiska J, Blomqvist C, Drapkin R, Adams DJ, Nevanlinna H, Bartek J, Tarsounas M, Ganesan S, Jonkers
J. Nat Struct Mol Biol. (2010) 17, 688-95.

  PAX8 Reliably Distinguishes Ovarian Serous Tumors From Malignant Mesothelioma.
Laury AR, Hornick JL, Perets R, Krane JF, Corson J, Drapkin R, Hirsch MS.
Am J Surg Pathol (2010) 34, 627-635.
    
  An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells.
Qing Sheng, Xinggang Liu, Eleanor Fleming, Karen Yuan, Huiying Piao, Jinyun Chen, Zeinab Moustafa, Roman K. Thomas, Heidi Greulich, Anna Schinzel, Sara Zaghlul, David Batt, Seth Ettenberg, Matthew Meyerson, Birgit Schoeberl, Andrew L. Kung, William C. Hahn, Ronny Drapkin, David M. Livingston, and Joyce F. Liu.
Cancer Cell (2010) 17, 298–310.
    
  Ovarian Cancer Pathogenesis: A Model in Evolution.
Alison M. Karst and Ronny Drapkin.
Journal of Oncology (2010), 2010, article ID 932371, 13 pages.
    
  Overexpression of Elafin in Ovarian Carcinoma Is Driven by Genomic Gains and Activation of the Nuclear Factor B Pathway and Is Associated with Poor Overall Survival.
Adam Clauss, Vivian Ng, Joyce Liu, Huiying Piao, Moises Russo, Natalie Vena, Qing Sheng, Michelle S. Hirsch, Tomas Bonome, Ursula Matulonis, Azra H. Ligon, Michael J. Birrer, and Ronny Drapkin.
Neoplasia (2010), 12, 161–172.


Article Coverage and Highlights

  Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis.
K Levanon, V Ng, HY Piao, Yi Zhang, MC Chang, MH Roh, DW Kindelberger, MS Hirsch, CP Crum, JA Marto and R Drapkin.
Oncogene (2010) 29, 1103–1113.

Close


2008

  Does the fimbria have an embryologic origin distinct from that of the rest of the fallopian tube.
Leslie A. Garrett, M.D., Sara O. Vargas, M.D., Ronny Drapkin, M.D., Ph.D., and Marc R. Laufer, M.D.
Fertility and Sterility (2008) 90, e 5-8.
    
  New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact.
Keren Levanon, Christopher Crum, and Ronny Drapkin.
J Clinical Oncology (2008) 26, 5284-5293.
    
  Urokinase-Type Plasminogen Activator Receptor: A Beacon of Malignancy.
Ronny Drapkin, Adam Clauss, and Steven Skates.
Clin Cancer Res (2008) 14, 5643-5645.
    
  A Novel Breast Cancer ^Associated BRIP1 (FANCJ/BACH1) GermlineMutation Impairs Protein Stability and Function.
Arcangela DeNicolo, Mariella Tancredi, Grazia Lombardi, Cristina Chantal Flemma, Serena Barbuti, Claudio DiCristofano, Bijan Sobhian, Generoso Bevilacqua, Ronny Drapkin, and Maria Adelaide Caligo.
Clin Cancer Res (2008) 14, 4672-4800.

  A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.
Ann K. Folkins, Elke A. Jarboe, Aasia Saleemuddin, Yonghee Lee, Michael J. Callahan, Ronny Drapkin, Judy E. Garber, Michael G. Muto, Shelley Tworoger, Christopher P. Crum.
Gynecologic Oncology (2008) 109, 168–173.     
        
  Use of Yeast-Secreted In vivo Biotinylated Recombinant Antibodies (Biobodies) in Bead-Based ELISA.
Nathalie Scholler, Kimberly A. Lowe, Lindsay A. Bergan, Archana V. Kampani, Vivian Ng, Robin M. Forrest, Jason D.Thorpe, Jenny A. Gross, Barbara M. Garvik, Ronny Drapkin, Garnet L. Anderson, and Nicole Urban.
Clin Cancer Res (2008) 14, 2647-2655.

  Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective.
E A Jarboe, A K Folkins, R Drapkin, T A Ince, E S Agoston & C P Crum.
Histopathology (2008) 53, 127-138.

  A Molecular Signature of Gastric Metaplasia Arising in Response to Acute Parietal Cell Loss.
Koji Nozaki, Masako Ogawa, Janice A. Williams, Bonnie J. Lafleur, Vivian Ng, Ronny I. Drapkin, Jason C. Mills, Stephen F. Konieczny, Sachiyo Nomura, And James R. Goldenring.
Gastroenterology (2008) 134, 511–522.

Close


2007

  Distinctive Cytogenetic Profile in Benign Metastasizing Leiomyoma: Pathogenetic Implications.
Marisa R. Nucci, MD, Ronny Drapkin, MD, PhD, Paola Dal Cin, PhD, Christopher D. M. Fletcher, MD, FRCPath, and Jonathan A. Fletcher, MD.
Am J Surg Pathol. (2007); 31: 737-43, Number 5, May 2007.     
        
  Further Evidence for BRCA1 Communication with the Inactive X Chromosome.
Daniel P. Silver, Stoil D. Dimitrov, Jean Feunteun, Rebecca Gelman, Ronny Drapkin, Shihua D. Lu, Elena Shestakova, Soundarapandian Velmurugan, Nicholas DeNunzio, Serban Dragomir, Jessica Mar, Xiaoling Liu, Sven Rottenberg, Jos Jonkers, Shridar Ganesan, and David M. Livingston.
Cell 128, 991–1002, March 9, 2007.     
        
  Lessons from BRCA: The Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer.
Christopher P. Crum, MD; Ronny Drapkin, MD, PhD; David Kindelberger, MD; Fabiola Medeiros, MD; Alexander Miron, PhD; and Yonghee Lee, MD.
Clinical Medicine & Research (2007) 5, 35-44.
    
  A recurrent mutation in PALB2 in Finnish cancer families.
Hannele Erkko, Bing Xia, Jenni Nikkila, Johanna Schleutker, Kirsi Syrja¨koski, Arto Mannermaa, Anne Kallioniemi, Katri Pylka¨s, Sanna-Maria Karppinen, Katrin Rapakko, Alexander Miron, Qing Sheng, Guilan Li, Henna Mattila, Daphne W. Bell, Daniel A. Haber, Mervi Grip, Mervi Reiman, Arja Jukkola-Vuorinen, Aki Mustonen, Juha Kere, Lauri A. Aaltonen, Veli-Matti Kosma, Vesa Kataja, Ylermi Soini, Ronny I. Drapkin, David M. Livingston & Robert Winqvist.
Nature (2007) 446, 316-319.     
        
  The distal fallopian tube: a new model for pelvic serous carcinogenesis.
Christopher P. Crum, Ronny Drapkin, Alexander Miron, Tan A. Ince, Michael Muto, David W. Kindelberger and Yonghee Lee.
Current Opinion in Obstetrics and Gynecology 2007, 19:3–9.     
        
  Serous Carcinogenesis in the Fallopian Tube: A Descriptive Classification.
Elke Jarboe, M.D., Ann Folkins, M.D., Marisa R. Nucci, M.D., David Kindelberger, M.D., Ronny Drapkin, M.D., Ph.D., Alexander Miron, Ph.D., Yonghee Lee, M.D., and Christopher P. Crum, M.D.
Int J Gynecol Pahol (2008) 27, 1-9.     
        
  A candidate precursor to serous carcinoma that originates in the distal fallopian tube.
Y Lee, A Miron, R Drapkin, MR Nucci, F Medeiros, A Saleemuddin, J Garber, C Birch, H Mou, RW Gordon, DW Cramer, FD McKeon and CP Crum.
J Pathology (2007) 211, 26-35.

Close


2005

  Human Epididymis Protein 4 (HE4) Is a Secreted Glycoprotein that Is Overexpressed by Serous and Endometrioid Ovarian Carcinomas. Ronny Drapkin, Hans Henning von Horsten, Yafang Lin, Samuel C. Mok, Christopher P. Crum, William R. Welch, and Jonathan L. Hecht. Cancer Res 2005; 65: (6). March 15, 2005.     
        
  Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Chryssa Kanellopoulou, Stefan A. Muljo, Andrew L. Kung, Shridar Ganesan, Ronny Drapkin, Thomas Jenuwein, David M. Livingston, and Klaus Rajewsky. Genes Dev (2005) 19, 489-501.

Close


2004

  Expression of Candidate Tumor Markers in Ovarian Carcinoma and Benign Ovary: Evidence for a Link Between Epithelial Phenotype and Neoplasia.
Ronny Drapkin, Md, Phd, Christopher P. Crum, Md, AndJonathan L. Hecht, Md, Phd.
Human Pathology (2004) 35, 1014-1021.     
        
  The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations.
Sharon Cantor*, Ronny Drapkin*, Fan Zhang, Yafang Lin, Juliana Han, Sushmita Pamidi, and David M. Livingston, (*denotes equal contribution).
PNAS (2004) 101, 2357–2362.

Close


2003

  The Ubiquitin Ligase Activity in the DDB2 and CSA Complexes Is Differentially Regulated by the COP9 Signalosome in Response to DNA Damage.
Regina Groisman, Jolanta Polanowska, Isao Kuraoka, Jun-ichi Sawada, Masafumi Saijo, Ronny Drapkin, Alexei F. Kisselev, Kiyoji Tanaka, and Yoshihiro Nakatani.
Cell (2003) 113, 357-367.     
        
  Association of BRCA1 with the inactive X chromosome and XIST RNA.
Shridar Ganesan, Daniel P. Silver, Ronny Drapkin, Roger Greenberg, Jean Feunteun and David M. Livingston.
Phil Trans R. Soc. Land B Biol Sci. (2004) 359, 123-8.

Close


2002

  BRCA1 Supports XIST RNA Concentration on the Inactive X Chromosome.
Shridar Ganesan, Daniel P. Silver, Roger A. Greenberg, Dror Avni, Ronny Drapkin, Alexander Miron, Samuel C. Mok, Voahangy Randrianarison, Steven Brodie, Jennifer Salstrom, Theodore P. Rasmussen, Ann Klimke, Christine Marrese, York, Marahrens, Chu-Xia Deng, Jean Feunteun, and David M. Livingston.
Cell, Vol. 111, 393–405, November 1, 2002, Copyright 2002 by Cell Press.     
        
  RNA Synthesis.
Ronny Drapkin and Danny Reinberg.
ENCYCLOPEDIA OF LIFE SCIENCES / & 2002 Macmillan Publishers Ltd, Nature Publishg Group.     
        
  The origins of ovarian cancer: hurdles and progress.
Ronny Drapkin, MD, PhD, and Jonathan Hecht, MD, PhD.
Women’s Oncol Rev 2002;2:261–68.

Close


2001

  The p400 Complex Is an Essential E1A Transformation Target.
Miriam Fuchs, Jill Gerber, Ronny Drapkin, Said Sif, Tsuyoshi Ikura, Vasily Ogryzko, William S. Lane, Yoshihiro Nakatani, and David M. Livingston.
Cell, Vol. 106, 297–307, August 10, 2001, Copyright 2001 by Cell Press.     
        
  BACH1, a Novel Helicase-like Protein, Interacts Directly with BRCA1 and Contributes to Its DNA Repair Function.
Sharon B. Cantor,* Daphne W. Bell, Shridar Ganesan, Elizabeth M. Kass, Ronny Drapkin, Steven Grossman, Doke C.R. Wahrer, Dennis C. Sgroi, William S. Lane, Daniel A. Haber, David M. Livingston.
Cell, Vol. 105, 149–160, April 6, 2001, Copyright 2001 by Cell Press.

Close


1996

  A human RNA polymerase II complex associated with SRB and DNA-repair proteins.
Maldonado E, Shiekhattar R, Sheldon M, Cho H, Drapkin R, Rickert P, Lees E, Anderson CW, Linn S, Reinberg D.
Nature 1996 Nov 28;384(6607):384.     
        
  Human cyclin-dependent kinase-activating kinase exists in three distinct complexes.
Ronny Drapkin, Gary Le Roy, Helen Cho, Sasha Akoulitchev, and Danny Reinberg.
Proc. Natl. Acad. Sci. USA Vol. 93, pp. 6488–6493, June 1996 Biochemistry.

Close


1995

  The Epstein-Barr Virus Nuclear Protein 2 Acidic Domain Forms a Complex with a Novel Cellular Coactivator That Can Interact with TFIIE.
Xiao Tong, Ronny Drapkin, Ramana Yalamanchili, George Mosialos, And Elliott Kieff.
Molecular And Cellular Biology, Sept. 1995, p. 4735–4744.     
        
  The 62- and 80-kDa subunits of transcription factor IIH mediate the interaction with Epstein-Barr virus nuclear protein 2.
Tong X, Drapkin R, Reinberg D, Kieff E. Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3259-63.     
        
  Cdk-activating kinase complex is a component of human transcription factor TFIIH.
Shiekhattar R, Mermelstein F, Fisher RP, Drapkin R, Dynlacht B, Wessling HC, Morgan DO, Reinberg D.
Nature. 1995 Mar 16; 374(6519):283-7.

Close


1994

  The multifunctional TFIIH complex and transcriptional control.
Ronny Drapkin and Danny Reinberg.
Trends Biochem Sci (1994) 19, 504-508.     
        
  Where Transcription Meets Repair.
Ronny Drapkin, Aziz Sancar, and Danny Reinberg.
Cell. Vol. 77, 9-12, April 8, 1994, Copyright 0 1994 by Cell Press.     
        
  Dual role of TFIIH in DNA excision repair and in transcription by RNA polymerase II.
Drapkin R, Reardon JT, Ansari A, Huang JC, Zawel L, Ahn K, Sancar A, Reinberg D.
Nature. 1994 Apr 21; 368(6473):769-72.     
        
  The Essential Twist.
Ronny Drapkin and Danny Reinberg.
Nature (1994) 369, 523-524.     
        
  Regulation of RNA polymerase II transcription.
Ronny Drapkin, Alejandro Merino and Danny Reinberg.
Current Opinion in Cell Biology 1993, 5:469-476.

Close